Suchergebnisse - "Hosokawa, A"

PubPharm (104)

1

Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer : the FUGA-BT (JCOG1113) randomized phase III clinical trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2019

von Morizane, C. | Okusaka, T. | Mizusawa, J. | +35

CommentIn: Ann Oncol. 2019 Dec 1;30(12):1851-1852. - PMID 31638143

2

Investigation of piezoelectric anisotropy of bovine cortical bone at an ultrasound frequency by coupling an experiment and a simulation

enthalten in: The Journal of the Acoustical Society of America | 2017

von Hosokawa, A.

3

Experimental observation of piezoelectric effect in cancellous bone generated by ultrasound irradiation

enthalten in: The Journal of the Acoustical Society of America | 2016

von Hosokawa, A.

4

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2016

von Yamazaki, K. | Nagase, M. | Tamagawa, H. | +45

CommentIn: Ann Oncol. 2016 Aug;27(8):1372-4. - PMID 27358377

5

Proton pump inhibitor after endoscopic resection for esophageal squamous cell cancer : multicenter prospective randomized controlled trial

enthalten in: Journal of gastroenterology | 2016

von Kakushima, N. | Hori, K. | Ono, H. | +17

6

Proton pump inhibitor after endoscopic resection for esophageal squamous cell cancer: multicenter prospective randomized controlled trial

enthalten in: Journal of gastroenterology | 2016

von Kakushima, N. | Hori, K. | Ono, H. | +17

7

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

enthalten in: Annals of oncology | 2016

von Yamazaki, K. | Nagase, M. | Tamagawa, H. | +45

8

P-147Final analysis: phase II trial of Irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC: HGCSG0902. -comparison of administration interval in cetuximab treatment

enthalten in: Annals of oncology | 2016

von Yuki, S. | Komatsu, Y. | Nakatsumi, H. | +19

9

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

enthalten in: Annals of oncology | 2016

von Yamazaki, K. | Nagase, M. | Tamagawa, H. | +45

10

172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment

enthalten in: Annals of oncology | 2016

von Ando, T. | Yuki, S. | Nakatsumi, H. | +17

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]